Subscribe
e.g. organoids

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Foghorn® Therapeutics, Inc. announced the first patient has been dosed in the Phase I study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML.
[Foghorn® Therapeutics, Inc.]
Press Release
Published In
NewslettersHematopoiesis News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

Post-Translational Modification of CDK1–STAT3 Signaling by Fisetin Suppresses Pancreatic Cancer Stem Cell Properties

[Cell & Bioscience] Scientists demonstrated that CDK1 was correlated with prognosis and was highly expressed in pancreatic cancer tissue and gemcitabine-resistant cells
Cancer Stem Cell NewsNewslettersPancreatic Cell News
Read more

Decellularized Human Pancreatic Extracellular Matrix-Based Physiomimetic Microenvironment for Human Islet Culture

[Acta Biomaterialia] Researchers demonstrated that incorporating human pancreatic decellularized extracellular matrix within alginate microcapsules resulted in a significant increase in Glucose Stimulation Index and total insulin secreted by encapsulated human islets, compared to free islets and islets encapsulated in only alginate.
Extracellular Matrix NewsNewslettersPancreatic Cell News
Read more

FABP4 in Macrophages Facilitates Obesity-Associated Pancreatic Cancer Progression via the NLRP3/IL-1β Axis

[Cancer Letters] In vivo and in vitro experiments revealed that FABP4 induced macrophage-related inflammation to promote pancreatic cancer cell migration, invasion, and metastasis under obese condition.
NewslettersPancreatic Cell News
Read more
Brought to you by